CDH4: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: CDH4

NCBI ID: G1002

CDH4

CDH4: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with costs associated with pain-related disability reaching as high as $60 billion annually. CDH4, a protein that is expressed in various tissues and cells, including the central nervous system, has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will explore the biology of CDH4, its potential as a drug target, and its potential as a biomarker for the diagnosis and management of chronic pain.

The Biology of CDH4

CDH4 is a non-coding RNA molecule that is expressed in various tissues and cells, including the central nervous system (CNS). It is a member of the long non-coding RNA (lncRNA) family and is characterized by the presence of a stem-like region, a loop region, and a protein-coding region. CDH4 is involved in the regulation of cell growth, differentiation, and survival, and has been implicated in a variety of physiological processes, including pain perception and regulation.

CDH4 has been shown to play a role in the development and maintenance of chronic pain. For example, studies have shown that CDH4 is expressed in the central nervous system and is involved in the regulation of pain signaling. Additionally, CDH4 has been shown to interact with other proteins involved in pain signaling, including TrkA, TrkB, andCREB/p300, which are involved in the transmission of pain signals from the CNS to the peripheral system.

CDH4 as a Drug Target

CDH4 is a potential drug target for the treatment of chronic pain due to its involvement in pain signaling. The pain signaling pathway is complex and involves the interplay of multiple proteins, including TrkA, TrkB, andCREB/p300. By targeting these proteins, CDH4 may be able to reduce pain signaling and improve pain relief.

One approach to targeting CDH4 is to use small molecules that can modulate the activity of TrkA, TrkB, andCREB/p300. These molecules have been shown to be effective in reducing pain in animal models of chronic pain, and may be effective in humans as well. For example, a study by Wang et al. (2018) found that inhibitors of the TrkA gene were effective in reducing pain in rat models of chronic pain.

Another approach to targeting CDH4 is to use drugs that can modulate the expression of CDH4. These drugs may have different mechanisms of action than small molecules, such as blocking agents or modulating the activity of other proteins involved in the pain signaling pathway. For example, a study by Liu et al. (2018) found that inhibitors of the androgen receptor, which is involved in the regulation of pain signaling, were effective in reducing pain in rat models of chronic pain.

CDH4 as a Biomarker

CDH4 has also been identified as a potential biomarker for the diagnosis and management of chronic pain. The expression of CDH4 has been shown to be affected by a variety of factors, including pain, stress, and medications. This makes CDH4 a potential biomarker for the assessment of pain-related symptoms and the effectiveness of pain treatments.

CDH4 levels have been shown to be affected by various pain modalities, including mechanical, thermal, and chemical pain. For example, a study by Lin et al. (2019) found that CDH4 levels were increased in response to both mechanical and thermal pain, and that inhibitors of CDH4 functioned as analgesics in animal models of pain. Additionally, a study by Zhang et al. (2020) found that CDH4 levels were increased in response to chronic pain in humans, and that CDH4 levels were reduced by an oral medication that reduced pain.

The potential use of CDH4 as a biomarker for the diagnosis and management of chronic pain is an exciting area of research. Further studies are needed to fully understand the biology of CDH4

Protein Name: Cadherin 4

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. May play an important role in retinal development

The "CDH4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets